CMS had until Feb. 1 to announce the new batch of drugs chosen ... The drugs treat conditions such as diabetes and cancer, and seniors across the country rely on them,” President Joe Biden said in a statement. “The Inflation Reduction Act put the ...

The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started, so current drug prices are unaffected.

Famous and renowned strategist of the Democrats named James Carville quite recently asserted that no one in the US right now wants to hear anything whatsoever from former US President Joe Biden. He also said that due to some significant reasons everyone out there just hates former US President Joe Biden.

Barron Trump caught attention at the inauguration for his height and polite demeanor, exchanging greetings with Joe Biden and Kamala Harris. Social me

On Day 1 of his second term of office, Trump rescinded Biden's Executive Order 14087, "Lowering Prescription Drug Costs for Americans." Trump's action ha

The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs Ozempic, Wegovy and Rybelsus, for the second round of drug price negotiations, made possible through the Inflation | Likely to be the last defining health policy act as president,

Social media users observed Joe Biden’s presidential tenure missing from Google’s search results, with only Donald Trump’s terms visible. Screenshots

Since former-President Joe Biden's 2022 order, CMS had been planning out and preparing to test three models to lower prices. None of them had fully gone into effect. Therefore, current Medicare ...

Donald Trump’ s return to the White House— along with a GOP- controlled Senate and House of Representatives— is expected to change that. Republicans in Washington say they plan to use funding cuts and regulatory changes to dramatically shrink Medicaid,

New documents clarify how the FDA plans to regulate AI-enabled devices, experts say, but several important questions remain around insurance coverage and generative AI.

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, President Trump issued multiple executive orders that concern the industry.